the pharmacokinetics of recombinant human erythropoietin (rhuepo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. the half-life of circulating erythropoietin decreased from 7.9±oa hr (mean ±so) at the beginning of treatment to 6.2±o.6 hr after 6 weeks and 5a±o.9 hr after 4 months of treatment. in spite of the s...

The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of t...

Patients undergoing antiviral therapy for chronic hepatitis C often develop anemia secondary to ribavirin and interferon. Recombinant erythropoietin has been used to improve anemia associated with antiviral therapy and to minimize dose reductions, which are associated with decreased rates of sustained virologic response. A rare potential side effect of recombinant erythropoietin is anti-erythro...

The mechanism of action of erythropoietin is thought to require specific interaction with the target cell surface and involve alteration of cellular calcium metabolism. Using the rabbit reticulocyte membrane as a model of the immature red cell membrane, we investigated the effects of human recombinant erythropoietin on membrane Ca2+-ATPase (calcium pump) activity in vitro. Erythropoietin in a c...

BACKGROUND Recent evidence shows a selective destruction of the youngest circulating red blood cells (neocytolysis) trigged by a drop in erythropoietin levels. OBJECTIVE The aim of this study was to evaluate the effect of recombinant human erythropoietin beta on the red blood cell storage lesion and apoptosis indices under blood bank conditions. METHODS Each one of ten red blood cell units ...

Erythropoietin (EPO) regulation of red blood cell production and its induction at reduced oxygen tension provides for the important erythropoietic response to ischemic stress. The cloning and production of recombinant human EPO has led to its clinical use in patients with anemia for two and half decades and has facilitated studies of EPO action. Reports of animal and cell models of ischemic str...

Anaemia is a common problem in end stage kidney disease. Recombinant human erythropoietin (rHuEPO) is commonly used in management of such patients to maintain optimal hemoglobin levels and to minimise transfusion requirements. Acquired pure red cell aplasia (PRCA) is a rare complication of erythropoietin therapy due to development of anti-erythropoietin antibodies (anti-EPOabs). We report a pat...

background: erythropoietin (epo) is a glycoprotein hormone function to regulate the production of red blood cells. deficiency of epo is known to cause anemia in chronically infected renal patients and they require regular blood transfusion. availability of recombinant epo has eliminated the need for blood transfusion and now it is extensively used for the treatment of anemia. glycosylation of e...

Sir, In patients treated with recombinant human erythropoietin for anaemia of chronic renal failure, pure red-cell aplasia Fig 1. Time course of haemoglobin values and epoetin dose in a patient with anti-erythropoietin antibody induced PRCA.

normal 0 false false false en-us x-none fa microsoftinternetexplorer4 background : erythropoietin (epo) as a major stimulator of red blood cell (rbc) production play a key role on brain protection and have a caring effect on neurons from hypoxic or traumatic injury. the objective of this trial was to study the safety and efficacy of recombinant human epo (rhepo) on level of consciousness and ot...